AU7249198A - Substantially pure zonulin, a physiological modulator of mammalian tight junctions - Google Patents

Substantially pure zonulin, a physiological modulator of mammalian tight junctions

Info

Publication number
AU7249198A
AU7249198A AU72491/98A AU7249198A AU7249198A AU 7249198 A AU7249198 A AU 7249198A AU 72491/98 A AU72491/98 A AU 72491/98A AU 7249198 A AU7249198 A AU 7249198A AU 7249198 A AU7249198 A AU 7249198A
Authority
AU
Australia
Prior art keywords
substantially pure
tight junctions
zonulin
physiological modulator
mammalian tight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU72491/98A
Other languages
English (en)
Inventor
Alessio Fasano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Maryland Baltimore
Original Assignee
University of Maryland Baltimore
University of Maryland College Park
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Maryland Baltimore, University of Maryland College Park filed Critical University of Maryland Baltimore
Publication of AU7249198A publication Critical patent/AU7249198A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/839—Nerves; brain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/843—Digestive system
    • Y10S530/844—Stomach; intestine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Electrotherapy Devices (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Particle Accelerators (AREA)
  • Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU72491/98A 1997-05-21 1998-04-28 Substantially pure zonulin, a physiological modulator of mammalian tight junctions Abandoned AU7249198A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08859931 1997-05-21
US08/859,931 US5945510A (en) 1997-05-21 1997-05-21 Substantially pure zonulin, a physiological modulator of mammalian tight junctions
PCT/US1998/007636 WO1998052415A1 (en) 1997-05-21 1998-04-28 Substantially pure zonulin, a physiological modulator of mammalian tight junctions

Publications (1)

Publication Number Publication Date
AU7249198A true AU7249198A (en) 1998-12-11

Family

ID=25332088

Family Applications (1)

Application Number Title Priority Date Filing Date
AU72491/98A Abandoned AU7249198A (en) 1997-05-21 1998-04-28 Substantially pure zonulin, a physiological modulator of mammalian tight junctions

Country Status (10)

Country Link
US (1) US5945510A (enExample)
EP (1) EP0982988B1 (enExample)
JP (2) JP2001527572A (enExample)
AT (1) ATE250625T1 (enExample)
AU (1) AU7249198A (enExample)
CA (1) CA2290459A1 (enExample)
DE (1) DE69818450T2 (enExample)
DK (1) DK0982988T3 (enExample)
ES (1) ES2209133T3 (enExample)
WO (1) WO1998052415A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU745507B2 (en) * 1998-08-03 2002-03-21 University Of Maryland At Baltimore Peptide antagonists of zonulin and methods for use of the same

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5908825A (en) * 1997-01-09 1999-06-01 University Of Maryland At Baltimore Dosage composition for nasal delivery and method of use of the same
AU759641B2 (en) 1998-08-19 2003-04-17 Skyepharma Canada Inc. Injectable aqueous dispersions of propofol
US6733762B1 (en) 1998-09-14 2004-05-11 University Of Maryland, Baltimore Method of using Zot to inhibit lymphocyte proliferation in an antigen-specific manner
MXPA01002600A (es) * 1998-09-14 2002-04-08 Univ Maryland Metodo de usar zot o zonulina para inhibir la proliferacion linfocito en una manera antigeno-especifico.
AU782298B2 (en) 1999-10-04 2005-07-14 Nektar Therapeutics Polymer stabilized neuropeptides
AU2001249067A1 (en) * 2000-05-19 2001-12-03 University Of Maryland, Baltimore Method of use of peptide antagonists of zonulin to prevent or delay the onset ofdiabetes
US7034036B2 (en) * 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
EP1384469A1 (de) * 2002-07-25 2004-01-28 Cognis France S.A. Verfahren zum Schutz und zur Modulation von Tight Junctions
EP1384468A1 (de) * 2002-07-25 2004-01-28 Cognis France S.A. Verfahren zum Schutz und zur Modulation von Tight Junctions
AU2004259705B2 (en) * 2003-07-15 2009-04-23 University Of Maryland, Baltimore Agonist polypeptide of receptor for zot and zonulin
US20080038843A1 (en) * 2006-08-11 2008-02-14 University Of Maryland - Baltimore Method of diagnosing celiac disease
TW200637573A (en) * 2005-01-14 2006-11-01 Univ Maryland Peptide for delivery of mucosal vaccines
AR057058A1 (es) * 2005-06-09 2007-11-14 Alba Therapeutics Corp Metodo para usar antagonistas de zonulina para prevenir la perdida o para regenerar celulas pancreaticas
CN103301070A (zh) * 2006-02-09 2013-09-18 阿尔巴医疗公司 紧密连接效应子的制剂
US20070239520A1 (en) * 2006-03-31 2007-10-11 Devin Collins Motivational apparatus and method of motivation
US20090069247A1 (en) * 2006-10-06 2009-03-12 Blake Paterson Use of tight junction antagonists to treat inflammatory bowel disease
US8034776B2 (en) 2006-10-26 2011-10-11 Alba Therapeutics Corporation Materials and methods for the treatment of celiac disease
US20100144646A1 (en) * 2006-11-03 2010-06-10 Blake Paterson Method of diagnosing and treating asthma
WO2009023311A2 (en) * 2007-05-07 2009-02-19 Alba Therapeutics Corporation Transcutaneous delivery of therapeutic agents
WO2009006246A1 (en) * 2007-06-29 2009-01-08 Alea Therapeutics Corp. Use of tight junction antagonists in the treatment of acute long injury and acute respiratory distress syndrome
US8198233B2 (en) 2007-07-26 2012-06-12 Alba Therapeutics Corporation Synthetic peptides that enhance tight junction permeability
WO2013142279A1 (en) 2012-03-19 2013-09-26 Seachaid Pharmaceuticals, Inc. Dosing regimens for echinocandin class compounds
WO2016190310A1 (ja) * 2015-05-26 2016-12-01 国立大学法人名古屋大学 タイトジャンクションの緩和剤、該緩和剤を含む薬剤吸収補助剤、及び該緩和剤を含む医薬組成物
US20190358288A1 (en) 2017-02-10 2019-11-28 Innovate Biopharmaceuticals, Inc. Compositions and methods for treating or preventing environmental enteropathy
US11608359B2 (en) 2018-02-23 2023-03-21 9 Meters Biopharma, Inc. Compounds and methods for treating tight junction permeabtility

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665389A (en) * 1995-05-24 1997-09-09 University Of Maryland At Baltimore Oral dosage composition for intestinal delivery and method of treating diabetes

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU745507B2 (en) * 1998-08-03 2002-03-21 University Of Maryland At Baltimore Peptide antagonists of zonulin and methods for use of the same

Also Published As

Publication number Publication date
ATE250625T1 (de) 2003-10-15
EP0982988B1 (en) 2003-09-24
JP2005290008A (ja) 2005-10-20
US5945510A (en) 1999-08-31
CA2290459A1 (en) 1998-11-26
DE69818450D1 (de) 2003-10-30
DE69818450T2 (de) 2004-07-08
EP0982988A4 (en) 2000-04-05
ES2209133T3 (es) 2004-06-16
WO1998052415A1 (en) 1998-11-26
JP2001527572A (ja) 2001-12-25
EP0982988A1 (en) 2000-03-08
DK0982988T3 (da) 2004-01-19

Similar Documents

Publication Publication Date Title
AU7249198A (en) Substantially pure zonulin, a physiological modulator of mammalian tight junctions
AU6613896A (en) Chemical compounds
AU1179795A (en) Improved immunogenic compositions against human gastrin 17
AU1750097A (en) Highly concentrated, lyophilized, and liquid factor ix formulations
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
AU8974298A (en) 1,4,7,10-tetraazabicyclo{8.2.2}tetradecan-2-one, a process for the preparation thereof and the use thereof for the preparation of tetraazamacrocycles
ES2176456T3 (es) Procedimiento de preparacion de un compuesto inhibidor del vih proteasa.
AU4329396A (en) Use of 3,4-diphenylchromans
AU5982396A (en) The use of n,n'-bis(mercaptoacetyl) hydrazine drivatives as anticataract agents
AU8332791A (en) Oral pharmaceutical compositions containing melatonin
ES2109103T3 (es) Procedimiento para la preparacion de trialquilsilil-7 bacatina iii.
AU6633596A (en) Improved therapeutic agents
EP0783521B8 (en) Polypeptide compounds containing d-2-alkyltryptophan capable of promoting the release of growth hormone
AU6180896A (en) Improved synthesis of 2,4,6,8,10,12-hexabenzyl-2,4,6,8,10,12-hexaazatetracyclo{5.5 .0.05,9.03,11}dodecane
AU7517694A (en) Synthesis of 4,10-dinitro-2,6,8,12-tetraoxa-4,10-diazatetracyclo(5.5.0.05 ,9-03,11-)dodecane
AU4361696A (en) New uses of indolo-{2,3b}-quinoxalines
AU3893493A (en) Micro-organisms, preparation method therefor and uses thereof
AU6505898A (en) Sperm extender comprising native phosphocaseinate or beta-lactoglobulin, method for preparing same and uses
EP0717618A4 (en) STABILIZED FORMULATION FOR TABLETS
EP0739896A3 (de) Verfahren zur Herstellung von 6-Oxo-(6H)-dibenz-(c,e)(1,2)-oxaphosphorinen
BG104452A (en) New derivatives of the methylenebisphosphonic acid
CA2250844A1 (en) Anti-hiv composition comprising imidazole derivatives
AU5994696A (en) Modified alpha-d-glcp-(1-2)-alpha-d-glcp-(1-3)-alpha-d-glcp- analogues
AU5635496A (en) Derivatives of 2,3:4,6-di-o-isopropylidene-alpha-l-xylo-2-he xulofluranosonic acid
TW340108B (en) 1,1-difluoro-1,4-dichlorobutane and process for its preparation

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase